2013 08 07 Q A 193 Fasting on Watermelon, Cholesterol, Genetics Experiences
Web site: http://www.drmorsesherbalhealthclub.com Official YouTube channel: https://www.youtube.com/user/robertmorsend.

By: Aru Shizuka

Follow this link:
2013 08 07 Q&A 193 Fasting on Watermelon, Cholesterol, Genetics & Experiences - Video

Recommendation and review posted by Bethany Smith

EX-GEN - CLOSER (Extreme Genetics 0.2) - 3D Vision Recordings // Out 15/07/2k14
3DVEP010 EX-GEN EXTREME GENETICS 0.2 Tracklist: 01 CLOSER 02 PROMETHEUS with ABSOLUM 03 RETREAT The EX-GEN strike back !!! The scientists were hard at work i...

By: EX-GEN NANUK

The rest is here:
EX-GEN - CLOSER (Extreme Genetics 0.2) - 3D Vision Recordings // Out 15/07/2k14 - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics - Minecraft Mod
Minecraft Mod - Playlist: http://castcrafter.de/MinecraftMods Advanced Genetics: http://castcrafter.de/AdvancedGenetics Abonnieren: http://bit.ly/1qTeka2 Twitter: http://bit.ly/ZcZ...

By: CastCrafter

Read this article:
Advanced Genetics - Minecraft Mod - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

10-Jun-2014

Contact: Ronald Rogers rrogers@myriad.com 801-584-3065 Myriad Genetics, Inc.

SALT LAKE CITY, Utah, June 10, 2014 Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra DA data will be featured in eight posters at the 2014 European League Against Rheumatism (EULAR) Annual Meeting, June 11-14, 2014, in Paris, France. Vectra DA is a quantitative, objective multi-biomarker test to measure disease activity in patients with rheumatoid arthritis (RA). The Vectra DA test offers insight into the biological processes that drive disease activity to help rheumatologists manage RA and improve patient care.

At EULAR, data will be presented by researchers from the Swedish Farmacotherapy (SWEFOT) clinical trial that demonstrate the clinical utility of Vectra DA in assessing the risk of future joint damage at multiple points in time. Additionally, SWEFOT data indicate that changes in Vectra DA scores were associated with favorable response to both non-biologic and biologic therapies. Further, the data demonstrate that Vectra DA may have the potential to serve as an inclusion criterion for assessing patients who are candidates for clinical trials in rheumatoid arthritis.

"The breadth of data presented at EULAR is representative of the clinical utility of Vectra DA in the overall management of RA," said Oscar Segurado, chief medical officer at Crescendo Bioscience. "Vectra DA provides physicians with important, actionable insight to better assess risk of radiographic progression as well as manage therapy decisions in their patients with a precise and standardized tool. The EULAR data also point out the opportunity to identify more patients that may be eligible to participate in clinical trials."

The data to be presented at this EULAR meeting will build on a recently published study in the journal Annals of Rheumatic Diseases that demonstrated that Vectra DA scores at the start of the SWEFOT clinical study predicted radiographic progression of joint damage over the following year. The new data from the SWEFOT study being presented at EULAR demonstrate that Vectra DA scores at 3 months and 12 months also were predictive of subsequent radiographic progression over the following 2 years. Additionally, patients in the SWEFOT study who did not respond to 3 months of initial methotrexate therapy were randomized to receive either non-biological DMARD triple therapy or anti-TNF (infliximab) therapy. Patients with a high Vectra DA score at baseline that remained high following therapy were at a high risk for radiographic progression. By contrast, risk for progression was significantly lower among patients with a high Vectra DA score at baseline, but lower Vectra DA score following treatment. At all measured time points, low Vectra DA scores were associated with low risk for subsequent radiographic progression.

"These are clinically relevant findings for rheumatologists taking care of patients with RA," said Ronald F. van Vollenhoven, M.D., Ph.D, Department of Medicine, Karolinska Institute in Stockholm, Sweden. "These data show that Vectra DA may help identify those patients at higher and lower risks for radiographic progression while receiving antirheumatic therapy."

Poster Tour Presentations

Title: Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment. Presenter: Ronald van Vollenhoven Date: Presentation: June 13, 2014 12:00 PM, Room 251 Poster: June 14, 2014; 10:15 AM, Poster Area D, Level 4 Key Finding: In this analysis of the SWEFOT study, Vectra DA was found to be potentially useful as an inclusion criterion in clinical trials. Recruitment for clinical trials in patients with active RA may be enhanced by including patients with a Vectra DA score > 44 in addition to the conventional approach of only using patients with a CRP > 10 mg/L. This enhancement was achieved with a comparable response to treatment and subsequent radiographic progression. In this study the number of eligible DMARD nave patients increased by 24 percent and the number of eligible MTX Non-responder patients increased by 47 percent.

Visit link:
Crescendo Bioscience to present multiple studies at 2014 EULAR Meeting

Recommendation and review posted by Bethany Smith

Genetics start-up 23andMe said on Friday it is one step closer to resuming sales of its full-fledged health product, with the U.S. Food and Drug Administration accepting its first health report for review.

The home genetics company said in a blog post that the FDA will begin evaluating the company's submission for a 510(k) application, a regulatory process that applies to most medical devices sold in the United States.

Kathy Hibbs, 23andMe's chief legal and regulatory officer, said in the blog post that the submission focused on one single inherited condition, called Bloom Syndrome.

"Once cleared, it will help 23andMe, and the FDA, establish the parameters for future submissions,'' Hibbs writes.

Read More 3 promising tech darlings that fell flat

In November of 2013, the Google-backed firm stopped selling its $99 DNA test until it obtained marketing authorization from the FDA. 23andMe had previously said in its marketing materials that it could deliver insights about people's genetic predispositions toward "254 diseases and conditions.''

But in a public warning letter last November, addressed to 23andMe's chief executive Anne Wojcicki, the FDA expressed concerns about the "public health consequences of inaccurate results'' from 23andMe's genetic test kit.

Bradley Merrill Thompson, a product regulatory attorney with Epstein Becker & Green, said this was an important "milestone'' for 23andMe. The process may still take time, he added, as FDA will likely have further questions or requests for information.

Read More China's genomics success shows big data challenges

"But this does reveal 23andMe's strategyand that's to go through the process with the FDA.''

Read this article:
23andMe on path to FDA approval

Recommendation and review posted by Bethany Smith

Jazzmin, C5 SCI, on RT600 at Project Walk Atlanta -Spinal Cord Injury Recovery
a C5-C7 SCI complete injury, ASIA A No rehab place in Indiana would let her use this machine because they said she wouldn #39;t be able to, she said "WATCH ME". ...

By: Project Walk Atlanta-Paralysis Recovery Center, SCI MS

See the article here:
Jazzmin, C5 SCI, on RT600 at Project Walk Atlanta -Spinal Cord Injury Recovery - Video

Recommendation and review posted by sam

Rotimi Adesanya | credits: File copy

Treatment

Treatment for sickle cell anaemia (SS) is usually aimed at avoiding crises, relieving symptoms and preventing complications. A person with sickle cell anaemia will need to make regular visits to the hospital to check the red blood cell count and monitor his/her health.

Treatment may include antibiotics, vitamins, daily folic acid, blood transfusions, pain-relieving medicines, supplemental oxygen, fluid therapy and other medications; and possibly surgery to correct vision problems or to remove a damaged spleen.

Self/home management: It is advisable that a sickle cell patient drinks plenty of water, eat balanced diets that contain all classes of food in the right proportions, including fresh fruits and vegetables; take regular non strenuous exercises, keep warm in cold weather, and cool in hot weather.

Antibiotics: Children with sickle cell anaemia may begin taking the antibiotic penicillin when they are about two months of age and continue taking it until they are five years old.

Anti-malarials: Children with sickle cell anaemia should be given anti-malarial prophylaxis from time to time in order to prevent crises.

Pain-relieving medications: To relieve pain during a sickle crisis, over-the-counter pain relievers and application of heat to the affected area should be deployed. Stronger pain medication can also be prescribed by the doctor.

Dietary supplements: Ciklavite, Trevor, Jobelyn and many more are some dietary supplements (adjuvants) that play supportive role in the management of sickle cell disease.

Hydroxyurea: When taken daily, hydroxyurea reduces the frequency of painful crises and may reduce the need for blood transfusions. It may be an option for adults with severe case of the disease. It is only administered under strict medical supervision.

Read the rest here:
Managing sickle cell disorder (2)

Recommendation and review posted by Bethany Smith

By Jerome Burne

Published: 18:34 EST, 16 June 2014 | Updated: 18:34 EST, 16 June 2014

Fred had rare and aggressive cancer in his adrenal glands (illustrated) and lived for nearly three years thanks to highly sophisticated gene test

Fred Barker was diagnosed with a rare but aggressive form of cancer in his adrenal glands just over three years ago. It came as a dreadful shock to the 44-year-old.

Most patients with this sort of tumour have less than six months left.

But Fred lived for nearly three years thanks to a highly sophisticated gene test that's set to revolutionise the way cancers are treated.

This looks for certain genes in tumours - if the cancer has these genes, the patient can then be given drugs that are known to target them specifically.

More than 80per cent of doctors change the treatment plan for those in their care following genetic tumour testing, according to research presented at the American Society of Clinical Oncology earlier this month. In another study, patients with ovarian cancer who had the test had a 36per cent lower risk of death from their illness compared with those who didn't.

A similar test recently became available on the NHS, and nearly 1,000 patients with cancer that has spread have had it. But few UK oncologists are aware this testing is now available - and fewer patients know enough to be able to ask for it.

Fred was lucky - he was living in Perth, Australia, when he became ill. He had already undergone surgery and chemotherapy but scans had shown that his cancer was still growing and had spread to his spine, ribs and a shoulder blade.

Original post:
Gene test that transforms your chances of beating cancer

Recommendation and review posted by Bethany Smith

Movie Fun Run ICGEB 2014

By: International Centre for Genetic Engineering and Biotechnology

The rest is here:
Movie Fun Run ICGEB 2014 - Video

Recommendation and review posted by Bethany Smith

EDMONTON - If you, like many consumers, shop for food in the middle aisles of the grocery store where processed foods fill the shelves, you are likely buying products that contain genetically modified ingredients.

Yet you probably arent aware which products contain which modified ingredients, since in Canada there are no requirements that GM foods be labelled. Nor are you likely aware why and how the ingredients have been modified.

And, no doubt, youre unsure if it matters.

Genetic modification has been a polarizing issue since genetically modified seeds were first approved and planted in Canada in the mid-1990s. But with consumers increasingly keen to know where their food comes from, the topic of whats in their food is also attracting renewed attention.

I think people are genuinely interested in their food, says Ellen Goddard, a University of Alberta economist who studies consumer response to new technologies. Something about the GM debate has intrigued them. They want to know more about how their food is produced.

She adds: Consumers will almost always say they want more information.

Genetically modified organisms, popularly known as GMOs, are created when the genetic code is altered to either express a desirable trait or supress or remove an undesirable one. At its heart, genetic engineering is a short cut that speeds up the work of selective breeding, work that has been going on for centuries, but at a slower pace indeed, nearly every food crop grown today has been modified through this older process. Much of the opposition to genetic engineering of foods is focused on the practice of inserting genetic code from one organism into another, which cannot happen under natural circumstances.

Its this idea of mutant food forms that first spawned the Frankenfood nickname back in the 1990s.

The reality is only a few actual crops are genetically modified, but because they are widely used, they appear in many food products. The only GM crops grown in Canada are corn, soy, canola and sugar beets. But those crops are used in animal feed and as ingredients in thousands of processed foods on our grocery shelves. According to the Grocery Manufacturers Association, up to 75 per cent of conventional processed foods in a typical supermarket contain ingredients dervied from GMOs.

Go here to see the original:
Fields of gold ... or plains of ruin? The debate over genetically modified seeds in Alberta rages on

Recommendation and review posted by Bethany Smith

Attack of the B-TEAM | Super Modded Survival | #8 | Advanced Genetics!
8: We are still working on the base, just a quick update on whats going on and then some fun with advanced genetics also featuring +Beardlesskid https://w...

By: DadVsMinecraft

Link:
Attack of the B-TEAM | Super Modded Survival | #8 | Advanced Genetics! - Video

Recommendation and review posted by Bethany Smith

Our Next Grow: Iron Fist Genetics #2
Mail Order Bride Crossed with P91 BX looks amazing. 5 Roster Spots available. Live Lottery June 25th. Only at TheSocialGrow.com.

By: Green Clouds

Continued here:
Our Next Grow: Iron Fist Genetics #2 - Video

Recommendation and review posted by Bethany Smith

An Introduction to Mendelian Genetics
An introduction to Mendelian Genetics and inheritance. By Ross Firestone Visit us (http://www.khanacademy.org/science/healthcare-and-medicine) for health and...

By: khanacademymedicine

More here:
An Introduction to Mendelian Genetics - Video

Recommendation and review posted by Bethany Smith

"Old is Good" - Swedish Cancer Institute Personalized Medicine
http://SwedishCancerInstitute.org The Swedish Cancer Institute has a new weapon in the search for a cure. It #39;s personalized medicine, where DNA sequencing of a patient #39;s cancer cells helps...

By: swedishseattle

Read the original:
"Old is Good" - Swedish Cancer Institute Personalized Medicine - Video

Recommendation and review posted by sam

"Water Babies" - Swedish Cancer Institute Personalized Medicine
http://SwedishCancerInstitute.org The Swedish Cancer Institute has a new weapon in the search for a cure. It #39;s personalized medicine, where DNA sequencing of...

By: swedishseattle

Read the original:
"Water Babies" - Swedish Cancer Institute Personalized Medicine - Video

Recommendation and review posted by sam

Marshfield Clinic: Personalized Medicine Expertise TV Spot

By: Lindsay Stone Briggs

View post:
Marshfield Clinic: Personalized Medicine Expertise TV Spot - Video

Recommendation and review posted by sam

Fibromyalgia and spinal cord injury

By: mario juana

Link:
Fibromyalgia and spinal cord injury - Video

Recommendation and review posted by sam

Talking spinal cord injury: the family perspective
An extract from our Talking spinal cord injury: the family perspective DVD. Here Chris Cairns shares his experience of spinal cord injury. Chris #39;s brother, L...

By: Spinal Injuries

See the article here:
Talking spinal cord injury: the family perspective - Video

Recommendation and review posted by sam

| Spinal Cord Injury | Home Modifications (Full Video)

By: Stephanie Aiello

Read the original:
| Spinal Cord Injury | Home Modifications (Full Video) - Video

Recommendation and review posted by sam

Jazzmin gait training on RT600
C5 SCI, At project walk Atlanta spinal cord injury recovery 1st time up and a amazing response.

By: Tony Davenport

See the article here:
Jazzmin gait training on RT600 - Video

Recommendation and review posted by sam

San Francisco, California (PRWEB) June 19, 2014

The global market for artificial organ and bionics is expected to reach USD 38.75 billion by 2020 at an estimated CAGR of 9.3% from 2014 to 2020, according to a new study by Grand View Research, Inc. Increasing prevalence of acute renal failure and renal disorders due to lifestyle habits such as excessive alcohol consumption and growing geriatric population base causing a rise in organ failure rates is expected to serve this market as a high impact rendering driver. In addition, growing incidence rates of accidents is expected to boost the demand for organ transplants, thus increasing demand for artificial organ. Artificial kidney dominated the global market in 2013, with revenue estimated at over USD 12.21 billion; demand is expected grow due to the increasing chronic kidney patients. Artificial liver is the fastest growing market segment, at an estimated CAGR of 11.0% from 2014 to 2020.

The report Artificial Organ And Bionics Market Analysis By Product (Artificial Heart, Liver, Kidney, Pancreas, Bionic, Limbs, Heart Valves, Cardiac, Vision), By Technology (Mechanical, Electronic) And Segment Forecasts To 2020, is available now to Grand View Research customers at http://www.grandviewresearch.com/industry-analysis/artificial-organ-and-bionics

Request free sample of this report @ http://www.grandviewresearch.com/industry-analysis/artificial-organ-and-bionics/request.

Further key findings from the study suggest:

Browse all reports of this category @ http://www.grandviewresearch.com/industry/healthcare-it.

For the purpose of this study, Grand View Research has segmented the global artificial organ and bionics market on the basis of product, technology and region:

Browse all Grand View research upcoming reports @ http://www.grandviewresearch.com/ongoing-reports.

Latest Reports by Grand View Research:

Phytosterols Market Analysis By Application (Pharmaceutical, Cosmetics, Food Ingredients), By Product (Beta-Sitosterol, Campesterol, Stigmasterol, Ergosterol) And Segment Forecasts To 2020 (http://www.grandviewresearch.com/industry-analysis/phytosterols-market)

Continued here:
Artificial Organ & Bionics Market by Product (Artificial Heart, Liver, Kidney, Cardiac), by Technology (Mechanical ...

Recommendation and review posted by Bethany Smith

Originally published June 18, 2014 at 4:37 PM | Page modified June 19, 2014 at 8:32 PM

BELLINGHAM A decade ago, the San Juan Island owners of Comet brought their beloved golden retriever to Drs. Edmund Sullivan and Theresa Westfall at Bellingham Veterinary to see if Comets diagnosis of lymphoma could be treated as something other than a death sentence.

The odds werent good.

At the time, lymphoma was considered incurable, with chemotherapy treatment only a temporary solution because the cancer nearly always re-emerged and resulted in death within a year.

Sullivan and Westfall, who are married, were determined to help. After talking to Dr. Rainer Storb, an expert on human lymphoma at Fred Hutchinson Cancer Research Center in Seattle, they decided to attempt a bone-marrow transplant on Comet. They spent six months visiting the center to learn how.

After removing and preserving bone-marrow stem cells in a painless procedure, the cells are stored for re-injection after radiation therapy. Through DNA analysis, the patients cells are checked for the presence of tumor cells. Sometimes, blood transfusions are needed to provide platelets and red blood cells during recovery.

Its a common procedure in humans but hadnt been tried with dogs.

It worked. Comet survived.

Since Comets recovery, more than 100 dogs have been cured with the treatment through Bellingham Veterinary, and three more veterinary hospitals around the country have been trained in the procedure. The 50 percent cure rate is considered extraordinary.

I didnt invent the procedure, Sullivan says. The knowledge was already out there and we just applied it to dogs.

Link:
Lesson learned at Hutch helping dogs with lymphoma

Recommendation and review posted by Bethany Smith

MP calls for more donors in Pendle to register

11:43am Tuesday 17th June 2014 in News

THE Anthony Nolan charity is searching for more heroes in Pendle to join their bone marrow register in the fight against blood cancer.

Championed by Pendle MP Andrew Stephenson, this search is under way as the Anthony Nolan bone marrow register has been mapped across the UK by area for the first time.

In Pendle, there are more than 1,500 residents willing to donate their stem cells, or bone marrow, to save the life of a stranger.

Anthony Nolan, now in its 40th anniversary year, was the worlds first bone marrow register.

Mr Stephenson said: I am delighted that Pendle has one of the highest number of heroes on the register out of anywhere in Britain, but we could get even more.

Im hunting for more people to sign up today, so we can fight blood cancer together. It is something truly heroic to give a stranger a second chance at life. That is why Im proud of the huge number of Pendle residents already signed up and proud to champion this cause.

For details, visit www. anthonynolan.org/superhero.

View post:
MP calls for more donors in Pendle to register

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise DALLAS June 20, 2014 The Childrens Medical Center Research Institute at UTSouthwestern (CRI) has identified a biomarker that enables researchers to accurately characterize the properties and function of mesenchymal stem cells (MSCs) in the body. MSCs are the focus of nearly 200 active clinical trials registered with the National Institutes of Health, targeting conditions such as bone fractures, cartilage injury, degenerative disc disease, and osteoarthritis.

The finding, published in the journal Cell Stem Cell on June 19, significantly advances the field of MSC biology, and if the same biomarker identified in CRIs studies with mice works in humans, the outlook for clinical trials that use MSCs will be improved by the ability to better identify and characterize the relevant cells.

There has been an increasing amount of clinical interest in MSCs, but advances have been slow because researchers to date have been unable to identify MSCs and study their normal physiological function in the body, said Dr. Sean Morrison, Director of the Childrens Research Institute, Professor of Pediatrics at UTSouthwestern Medical Center, and a Howard Hughes Medical Institute Investigator. We found that a protein known as leptin receptor can serve as a biomarker to accurately identify MSCs in adult bone marrow in vivo, and that those MSCs are the primary source of new bone formation and bone repair after injury.

In the course of their investigation, the CRI researchers found that leptin receptor-positive MSCs are also the main source of factors that promote the maintenance of blood-forming stem cells in the bone marrow.

Unfortunately, many clinical trials that are testing potential therapies using MSCs have been hampered by the use of poorly characterized and impure collections of cultured cells, said Dr. Morrison, senior author of the study and holder of the Mary McDermott Cook Chair in Pediatric Genetics at UTSouthwestern. If this finding is duplicated in our studies with human MSCs, then it will improve the characterization of MSCs that are used clinically and could increase the probability of success for well-designed clinical trials using MSCs.

Dr. Bo Zhou, a postdoctoral research fellow in Dr. Morrisons laboratory, was first author of the paper. Other CRI researchers involved in the study were Drs. Rui Yue and Malea Murphy, both postdoctoral research fellows. The research was supported by the National Heart, Lung, and Blood Institute, the Cancer Prevention and Research Institute of Texas, and donors to the Childrens Medical Center Foundation.

About CRI

Childrens Medical Center Research Institute at UTSouthwestern (CRI) is a joint venture established in2011 to build upon the comprehensive clinical expertise of Childrens Medical Center of Dallas and the internationally recognized scientific excellence of UTSouthwestern Medical Center. CRIs mission is to perform transformative biomedical research to better understand the biological basis of disease, seeking breakthroughs that can change scientific fields and yield new strategies for treating disease. Located in Dallas, Texas, CRI is creating interdisciplinary groups of exceptional scientists and physicians to pursue research at the interface of regenerative medicine, cancer biology and metabolism, fields that hold uncommon potential for advancing science and medicine. More information about CRI is available on its website: cri.utsw.edu

Read more:
Children's Research Institute Finds Key to Identifying, Enriching Mesenchymal Stem Cells

Recommendation and review posted by Bethany Smith

FRESNO, Calif. (KFSN) --

It's something Jon Galvan experienced five years ago after he almost died from a hemorrhagic stroke while atSubmit work.

"I was typing away and I felt a pop in my head," Galvan told Ivanhoe.

He was able to recover, but Abba Zubair, MD, PhD, Medical Director of Transfusion Medicine and Stem Cell Therapy at Mayo Clinic, Florida says not everyone is as fortunate.

"If it happens, you either recover completely or die," Dr. Zubair told Ivanhoe. "That's what killed my mother."

SubmitDr. Zubair wants to send bone marrow derived stem cells to the international space station.

"Based on our experience with bone marrow transplant you need about 200 to 500 million cells," Dr. Zubair said.

But conventionally grown stem cells take a month. Experiments on earth have shown that stem cells will grow faster in less gravity.

"Five to ten times faster, but it could be more," Dr. Zubair said.

Specifically he hopes to expand the number of stem cells that will help regeneration of neurons and blood vessels in hemorrhagic stroke patients.

The rest is here:
Growing Stem Cells in Space: Medicine's Next Big Thing?

Recommendation and review posted by Bethany Smith